GlassScriptPhysician profile
Juan Francisco Arguello
NPI 1255497228
$7,670.63
in general payments reported to CMS, 2019-2025
24 companies · $254 in 2025
The $254 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,063 · 2020: $432 · 2021: $1,695 · 2022: $1,423 · 2023: $1,764 · 2024: $1,040 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,057.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,951.03 | 2019-2025 | Rinvoq, Skyrizi |
| Gilead Sciences, INC. | $869.62 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $758.37 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $493.77 | 2019-2024 | Ocaliva |
| Janssen Biotech, INC. | $427.50 | 2019-2024 | Stelara, Simponi Aria, Simponi |
| Allergan, INC. | $332.96 | 2019 | |
| Merck Sharp & Dohme LLC | $305.81 | 2021-2024 | Delstrigo, Pifeltro, Isentress |
| Janssen Scientific Affairs, LLC | $253.30 | 2022 | |
| Phathom Pharmaceuticals, INC. | $248.85 | 2024 | Voquezna |
| Nestle Healthcare Nutrition INC. | $248.39 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $238.61 | 2021-2023 | Zeposia |
| Lucid Diagnostics INC. | $234.64 | 2022-2023 | |
| Redhill Biopharma INC. | $224.28 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $200.10 | 2019-2021 | |
| Erbe USA INC | $198.52 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $172.14 | 2022-2023 | Rebyota |
| Exact Sciences Corporation | $137.85 | 2023 | Cologuard Collection Kit |
| Genzyme Corporation | $120.39 | 2022 | |
| Lilly USA, LLC | $111.75 | 2024 | Omvoh |
| Ironwood Pharmaceuticals, INC | $37.30 | 2021-2022 | |
| Celltrion USA INC. | $34.72 | 2024 | Zymfentra |
| Celgene Corporation | $29.78 | 2021 | |
| Daiichi Sankyo INC. | $22.67 | 2021 | |
| Alfasigma USA, INC. | $18.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Arguello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.